Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160160 | 0.87 | MEN1 (0.36) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL313033 | 0.73 | — | — | |
| SCHEMBL4495411 | 0.71 | GAA (0.44) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL3543729 | 0.71 | TSHR (0.32) | — | |
| SCHEMBL293197 | 0.71 | GAA (0.44) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL13444608 | 0.71 | GAA (0.44) | MEN1GAAKMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7430822 | 0.69 | GAA (0.48) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL18320613 | 0.69 | MEN1 (0.43) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL123812 | 0.66 | GAA (0.54) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL29408147 | 0.66 | GAA (0.54) | MEN1GAAKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMA CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2746272-A1 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20120225866-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1912644-A2 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007010138-A2 | N(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | WO | disclosed |
| EP-1286673-B8 | LIGANDS OF INTEGRIN RECEPTORS | ABBOTT GMBH & CO KG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1286673-A2 | LIGANDS OF INTEGRIN RECEPTORS | Basf Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| WO-2001093840-A2 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MEN1 3122/4885GAA 14/4885KMT2A 3895/4885 |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | MEN1 1708/4885GAA 4857/4885KMT2A 2496/4885 |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | MEN1 1708/4885GAA 4857/4885KMT2A 2496/4885 |
| US-20120225866-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | MEN1 1708/4885GAA 4857/4885KMT2A 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.